Stockreport

Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements

Tarsus Pharmaceuticals, Inc.  (TARS) 
PDF Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the [Read more]